Evidence map›Paper›PMID 28245266›Full record

ArticlePloS one2017

Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia.

Fu-Chun Zhou, Chuan-Yue Wang, Gabor S Ungvari, Chee H Ng, Yan Zhou, Liang Zhang, Jingjing Zhou, David H K Shum, David Man, Deng-Tang Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fu-Chun ZhouBeijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Chuan-Yue WangBeijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Gabor S UngvariThe University of Notre Dame Australia / Marian Centre, Perth, Australia.
Chee H NgDepartment of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
Yan ZhouBeijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Liang ZhangBeijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Jingjing ZhouBeijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
David H K ShumMenzies Health Institute Queensland and School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia.
David ManDepartment of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong SAR, China.
Deng-Tang LiuDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jun LiState Key Laboratory of Cognitive Neuroscience and Learning, Beijing, China.
Yu-Tao XiangUnit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China.

Funding

Role of microRNAs in HSC-mediated fibrogenesisR21AA022702 · NIAAA · CAROLINAS MEDICAL CENTER · PI SCHRUM, LAURA W · 2015 to 2016
$378k
NIAAA NIH HHS R21 AA022702
6 · The paper itself

Abstract

This study aimed to investigate prospective memory (PM) and the association with clinical factors at 1-year follow-up in first-episode schizophrenia (FES). Thirty-two FES patients recruited from a university-affiliated psychiatric hospital in Beijing and 17 healthy community controls (HCs) were included. Time- and event-based PM (TBPM and EBPM) performances were measured with the Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) at baseline and at one-year follow-up. A number of other neurocognitive tests were also administered. Remission was determined at the endpoint according to the PANSS score ≤ 3 for selected items. Repeated measures analysis of variance revealed a significant interaction between time (baseline vs. endpoint) and group (FES vs. HCs) for EBPM (F(1, 44) = 8.8, p = 0.005) and for all neurocognitive components. Paired samples t-tests showed significant improvement in EBPM in FES (13.1±3.7 vs. 10.3±4.8; t = 3.065, p = 0.004), compared to HCs (15.7±3.6 vs. 16.5±2.3; t = -1.248, p = 0.230). A remission rate of 59.4% was found in the FES group. Analysis of covariance revealed that remitters performed significantly better on EBPM (14.9±2.6 vs. 10.4±3.6; F(1, 25) = 12.2, p = 0.002) than non-remitters at study endpoint. The association between EBPM and 12-month clinical improvement in FES suggests that EBPM may be a potential neurocognitive marker for the effectiveness of standard pharmacotherapy. Furthermore, the findings also imply that PM may not be strictly a trait-related endophenotype as indicated in previous studies.

Indexed as

Memory, EpisodicAdolescentAdultAnalysis of VarianceCase-Control StudiesChinaFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMemory DisordersMiddle AgedNeuropsychological TestsPhenotypeProspective Studies

Identifiers

PMID28245266
PMCPMC5330457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.